Bayer shares surged on Monday after the company reported encouraging late-stage clinical trial results for its experimental cardiovascular drug asundexian, offering a rare boost for a pharmaceutical division that has struggled with setbacks and mounting litigation costs. The stock rose more than 9% and traded at €30.30—its highest level in…
This sharp contraction in overseas shipments has been attributed by industry officials and analysts primarily to the implementation of…
Bets for a December interest rate cut by the US Federal Reserve have sharply increased on Friday after an…
This week’s LATAM crypto news includes key developments: El Salvador continues to aggressively accumulate Bitcoin, pushing national reserves above…
JPMorgan’s senior analyst Kian Abouhossein has outlined his preferred European bank stocks as investors look ahead to 2026.Despite macroeconomic…
Bridgewater Associates founder Ray Dalio believes artificial intelligence spending has created bubble‑like conditions in financial markets.Yet despite the froth,…
The crash of an Indian-made Tejas fighter jet during a display at the Dubai Air Show has deepened scrutiny…
The global liquidity cycle is entering a decisive contraction phase, raising the risk of a prolonged downturn in equity…
Ibovespa futures started Friday down after the holiday of Black Awareness Day under the pressure of global risk aversion and…